Ulrich Germing

Summary

Affiliation: Heinrich Heine University
Country: Germany

Publications

  1. doi request reprint Prognostic scoring systems in MDS
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Duesseldorf, Duesseldorf, Germany
    Leuk Res 36:1463-9. 2012
  2. doi request reprint Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study
    U Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Leukemia 26:1286-92. 2012
  3. doi request reprint Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Duesseldorf, Duesseldorf, Germany
    Leuk Res 36:727-34. 2012
  4. ncbi request reprint Risk assessment in chronic myelomonocytic leukemia (CMML)
    U Germing
    Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Leuk Lymphoma 45:1311-8. 2004
  5. ncbi request reprint Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Moorenstr 5, 40225 Dusseldorf, Germany
    Haematologica 91:1596-604. 2006
  6. doi request reprint Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, 40225 Dusseldorf, Germany
    Ann Hematol 87:691-9. 2008
  7. ncbi request reprint Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients
    U Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, 40225, Dusseldorf, Germany
    Leuk Res 24:983-92. 2000
  8. ncbi request reprint Chronic myelomonocytic leukemia in the light of the WHO proposals
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Haematologica 92:974-7. 2007
  9. ncbi request reprint [Myelodysplastic syndromes--new treatment options]
    Ulrich Germing
    Klinik für Hämatologie, Onkologie und klinische Immunologie, Universitätsklinik Düsseldorf
    Med Klin (Munich) 101:123-6. 2006
  10. ncbi request reprint No increase in age-specific incidence of myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Dusseldorf, Germany
    Haematologica 89:905-10. 2004

Detail Information

Publications83

  1. doi request reprint Prognostic scoring systems in MDS
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Duesseldorf, Duesseldorf, Germany
    Leuk Res 36:1463-9. 2012
    ....
  2. doi request reprint Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study
    U Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Leukemia 26:1286-92. 2012
    ..In conclusion, patients with MDS and del(5q) are facing a considerable risk of AML transformation. More detailed cytogenetic and molecular studies may help to identify the patients at risk of progression...
  3. doi request reprint Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Duesseldorf, Duesseldorf, Germany
    Leuk Res 36:727-34. 2012
    ..The frequency of dysplastic changes did not differ significantly among the WHO types with the exception of MDS with del(5q) and CMML types. No single sign of dysplasia is exclusive for the diagnosis of MDS...
  4. ncbi request reprint Risk assessment in chronic myelomonocytic leukemia (CMML)
    U Germing
    Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Leuk Lymphoma 45:1311-8. 2004
    ..These scores should therefore be employed for clinical decision making and for risk stratification in the context of clinical trials...
  5. ncbi request reprint Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Moorenstr 5, 40225 Dusseldorf, Germany
    Haematologica 91:1596-604. 2006
    ..The aim of this study was a prospective validation of the World Health Organization (WHO) proposals for the classification of myelodysplastic syndromes (MDS) with respect to their prognostic relevance...
  6. doi request reprint Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, 40225 Dusseldorf, Germany
    Ann Hematol 87:691-9. 2008
    ..The dysplastic prodrome of acute myeloid leukemia in Down syndrome is classified within myeloid leukemia in Down syndrome and excluded from the population-based studies of MDS...
  7. ncbi request reprint Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients
    U Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, 40225, Dusseldorf, Germany
    Leuk Res 24:983-92. 2000
    ..In summary, the WHO classification appears to define morphological subgroups that are more homogeneous with respect to prognosis than the FAB subtypes...
  8. ncbi request reprint Chronic myelomonocytic leukemia in the light of the WHO proposals
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Haematologica 92:974-7. 2007
    ..No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classifi-cation of CMML...
  9. ncbi request reprint [Myelodysplastic syndromes--new treatment options]
    Ulrich Germing
    Klinik für Hämatologie, Onkologie und klinische Immunologie, Universitätsklinik Düsseldorf
    Med Klin (Munich) 101:123-6. 2006
    ..In the near future, the aim is not only to improve quality of life but also to prolong life expectancy...
  10. ncbi request reprint No increase in age-specific incidence of myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Dusseldorf, Germany
    Haematologica 89:905-10. 2004
    ..Epidemiological data on myelodysplastic syndromes (MDS) are sparse. However, the available evidence indicates that MDS is among the most common hematologic diseases...
  11. ncbi request reprint Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals
    Corinna Strupp
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstreet 5, 40225 Dusseldorf, Germany
    Leuk Res 27:397-404. 2003
    ....
  12. doi request reprint Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry
    Judith Neukirchen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Leuk Res 36:1067-70. 2012
    ..Median SF was 1954 ng/ml in chelated and 875 ng/ml in non-chelated patients. The difference in median survival (74 vs. 49 months, respectively; p=0.002) supports the idea that iron chelation therapy is beneficial for MDS patients...
  13. doi request reprint Impact on survival of different treatments for myelodysplastic syndromes (MDS)
    Kathrin Nachtkamp
    Department of Haematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Leuk Res 33:1024-8. 2009
    ..With the exception of allo-SCT, MDS treatment was generally palliative. Recently, epigenetic treatment with demethylating agents proved to be the first therapy that can significantly prolong survival in patients with higher-risk MDS...
  14. ncbi request reprint Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes
    Sabine Knipp
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Cancer 110:345-52. 2007
    ..It is unclear whether intensive chemotherapy is beneficial to patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) if they are aged >/=60 years...
  15. ncbi request reprint Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Ann Hematol 84:61-6. 2005
    ..For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs. If patients relapse after an initial response to VPA, ATRA has the potential to induce a prolonged second response...
  16. ncbi request reprint The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Cancer 106:112-9. 2006
    ..Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all-trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro...
  17. ncbi request reprint Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals
    Ulrich Germing
    Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Br J Haematol 132:162-7. 2006
    ....
  18. pmc The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome
    Esther Zipperer
    Department of Haematology, Oncology and Clinical Immunology Heinrich Heine University, Moorenstrasse 5, Dusseldorf, Germany
    Haematologica 94:729-32. 2009
    ..Considering their prognostic impact, comorbidities of MDS patients should receive appropriate attention in clinical trials as well as day-to-day clinical decision making...
  19. doi request reprint Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes
    Judith Neukirchen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Duesseldorf, Moorenstrasse 5, D 40225 Duesseldorf, Germany
    Eur J Haematol 83:477-82. 2009
    ..However, there are hardly any studies on the clinical relevance of low platelet counts in MDS...
  20. doi request reprint Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen
    Christian Saure
    Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany
    Biol Blood Marrow Transplant 18:466-72. 2012
    ..Our results add to the body of evidence that a FLAMSA-based sequential conditioning therapy is effective for previously untreated patients with high-risk MDS or sAML...
  21. ncbi request reprint Myelodysplastic syndromes in patients younger than age 50
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, and Institute of Human Genetics, Heinrich Heine University, Duesseldorf, Germany
    J Clin Oncol 24:5358-65. 2006
    ..The latter require special consideration to identify suitable candidates for allogeneic stem-cell transplantation, a potentially curative approach carrying a high risk of treatment-related complications...
  22. ncbi request reprint Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia
    Detlef Trost
    Institute of Human Genetics and Anthropology, Heinrich Heine University, Universitatsstrasse 1, 40225 Dusseldorf, Germany
    Cancer Genet Cytogenet 165:51-63. 2006
    ..Correlation with clinical parameters may reveal the prognostic significance of these genetic subgroups...
  23. doi request reprint Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts
    Anna Maassen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Leuk Res 37:64-70. 2013
    ..There was no difference in prognosis between RCMD and MDS-U and between RA, RT, and RN. The separation of RA, RN, and RT is not justified suggesting a consolidation as RCUD. MDS-U should be integrated into RCMD...
  24. ncbi request reprint Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation
    Thorsten Graef
    Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany
    Hematol Oncol 25:170-7. 2007
    ..In this study, the clinical benefit of a lower toxicity regimen was offset by higher RR resulting in inferior results in the non-MA group, especially when no CR was achieved by prior induction or salvage therapy...
  25. doi request reprint Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome
    Esther Zipperer
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, 40225, Dusseldorf, Germany
    Ann Hematol 92:1617-23. 2013
    ..Measurement of serum hepcidin with an improved ELISA yield results that correlate with other parameters of iron metabolism as well as survival and transfusion needs...
  26. ncbi request reprint Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia
    Brigitte Royer-Pokora
    Institute of Human Genetics and Anthropology, Heinrich Heine University, Dusseldorf, Germany
    Cancer Genet Cytogenet 167:66-9. 2006
    ..This demonstrates that a low blast count can be associated with a high proportion of 5q- cells in the bone marrow...
  27. doi request reprint Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry
    Judith Neukirchen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Leuk Res 35:1591-6. 2011
    ..15/100,000/year and the point prevalence per 100,000 persons of 7. We found that the incidence and prevalence of MDS was higher in men than women and increased sharply with increasing age...
  28. pmc Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival
    Akos Czibere
    Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf Moorenstrasse 5, 40225 Duesseldorf, Germany
    Haematologica 94:1453-5. 2009
    ..0249). Using multivariate analysis, the RPS14 expression status was confirmed as an independent predictor for survival in INT-1 patients...
  29. ncbi request reprint Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma
    Frank Neumann
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf Moorenstr 5, 40225, Duesseldorf, Germany
    Ann Hematol 85:530-4. 2006
    ..We conclude that a prolonged Rituximab maintenance therapy after PBSCT with monthly administration is reliable and safe...
  30. doi request reprint Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy
    Sebastian Balleisen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Leuk Res 33:1189-93. 2009
    ..Patients with a persisting abnormal karyotype must be regarded as high-risk patients who should receive intensified treatment...
  31. ncbi request reprint Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics
    Detlef Trost
    Institute of Human Genetics and Anthropology, Heinrich Heine University, Universitatsstr 1, 40225 Dusseldorf, Germany
    Leuk Res 28:171-7. 2004
    ..The low frequency and unclear prognostic value of I-FISH anomalies in MDS related AML suggests that these alterations play a minor role for AML evolution...
  32. doi request reprint Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes
    Michael Wulfert
    Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich Heine Universitat, Dusseldorf, Germany
    Exp Hematol 36:577-86. 2008
    ..To determine the frequency and spectrum of somatic mutations of mitochondrial DNA (mtDNA) in bone marrow of patients with myelodysplastic syndrome (MDS)...
  33. doi request reprint [Rationale for bone marrow examination in patients with inflammatory rheumatic diseases]
    Jutta G Richter
    Klinik fur Endokrinologie, Diabetologie und Rheumatologie, Heinrich Heine Universitat Dusseldorf, Dusseldorf, Germany
    Wien Klin Wochenschr 121:690-9. 2009
    ..Our objective was to explore indications for and results of bone marrow examinations in a large cohort...
  34. doi request reprint Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia
    Frank Neumann
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Moorenstr 5, 40225 Duesseldorf, Germany
    Leuk Res 33:232-6. 2009
    ..Using multivariate analysis we found the B2M level at the time of diagnosis to be an independent prognostic parameter for survival and for the risk of developing AML in high-risk MDS patients...
  35. ncbi request reprint Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Blood 104:1266-9. 2004
    ..Thus, VPA is of therapeutic benefit for patients with MDS, and ATRA may be effective when added later...
  36. ncbi request reprint Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes
    Carlo Aul
    Department of Hematology, Oncology and Immunology, St Johannes Hospital Duisburg, Medizinische Klinik II, An der Abtei 7 11, 47166 Duisburg, Germany
    Rev Clin Exp Hematol 8:E1. 2004
    ....
  37. ncbi request reprint Differences in epidemiology of MDS between Western and Eastern countries: Ethnic differences or environmental influence?
    Andrea Kuendgen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, 40225 Dusseldorf, Germany
    Leuk Res 31:103-4. 2007
    ....
  38. doi request reprint [Practice of recognizing benzene-caused occupational diseases in 2006]
    Stefanie Beelte
    Landesinstitut für Gesundheit und Arbeit des Landes Nordrhein Westfalen, Zentrum für Gesundheit in der Arbeit, Dusseldorf, Germany
    Med Klin (Munich) 103:553-60. 2008
    ..1303 of the appendix of the German ordinance on ODs. The aim of this study is to analyze the most important criteria that determined whether these diseases were recognized or rejected as ODs according to No. 1303 in 2006...
  39. doi request reprint Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome
    Wolf C Prall
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Int J Hematol 89:173-87. 2009
    ..Furthermore, our findings may help to define new molecular targets for drug development and therapeutic approaches for patients with poor prognosis...
  40. doi request reprint The sepsis-related Organ Failure Assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation
    Frank Neumann
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
    Ann Hematol 87:299-304. 2008
    ..After univariate and multivariate analysis the SOFA score discriminated survivors and non-survivors of the ICU stay. We conclude that the SOFA score is predictive for survival when applied on the day of ICU admission...
  41. doi request reprint The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany
    Norbert Gattermann
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Eur J Haematol 91:473-82. 2013
    ..As cytogenetic analysis and risk assessment are essential for the choice of appropriate therapy, elderly patients in particular may not be receiving adequate treatment...
  42. doi request reprint Prognostic molecular markers in myelodysplastic syndromes
    Judith Neukirchen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University of Duesseldorf, Moorenstraße 5, Duesseldorf, Germany
    Expert Rev Hematol 2:563-75. 2009
    ....
  43. doi request reprint Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysis
    Norbert Gattermann
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Onkologie 35:350-6. 2012
    ..Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic stem cell disorders...
  44. ncbi request reprint Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome
    Norbert Gattermann
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Moorenstr 5, D 40225 Dusseldorf, Germany
    Blood 103:1499-502. 2004
    ..Mitochondrial tRNA mutations impair mitochondrial protein synthesis, thereby causing dysfunction of the mitochondrial respiratory chain. We propose that this effect contributed to ineffective hematopoiesis in our patient...
  45. ncbi request reprint Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation
    Guido Kobbe
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Moorenstrasse 5, D 40225 Dusseldorf, Germany
    Transplantation 74:1198-200. 2002
    ..Treatment of secondary cancer after solid-organ transplantation is difficult because of coexisting medical conditions, reduced organ function, or advanced age in most patients...
  46. pmc Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes
    Julia Fröbel
    Department of Hematology, Heinrich Heine University, 40225 Dusseldorf, Germany
    Mol Cell Proteomics 12:1272-80. 2013
    ....
  47. doi request reprint Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow
    Judith Neukirchen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, 40225, Dusseldorf, Germany
    Ann Hematol 93:65-9. 2014
    ..Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated. ..
  48. doi request reprint Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study
    Judith Neukirchen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany Electronic address
    Leuk Res 38:57-64. 2014
    ..When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R. ..
  49. pmc Myelodysplastic syndromes: diagnosis, prognosis, and treatment
    Ulrich Germing
    Department of Haematology, Oncology and Clinical Immunology, Dusseldorf University Hospital
    Dtsch Arztebl Int 110:783-90. 2013
    ..Their clinical course is highly variable. About one-quarter of all patients with MDS develop acute leukemia. The median survival time from the moment of diagnosis is about 30 months...
  50. ncbi request reprint Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning
    Guido Kobbe
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Exp Hematol 30:1346-53. 2002
    ..To avoid high-dose conditioning and evaluate engraftment, toxicity, and GvT reactions, we treated a group of high-risk patients with a minimal intensive conditioning regimen followed by allogeneic BSCT...
  51. pmc Therapy-related myeloid neoplasms following treatment with radioiodine
    Thomas Schroeder
    Department for Haematology, Oncology and Clinical Immunology, University of Duesseldorf Medical Faculty, Duesseldorf, Germany
    Haematologica 97:206-12. 2012
    ..Few data are available on therapy-related myelodysplastic syndromes and acute myeloid leukemia developing after radioiodine treatment...
  52. ncbi request reprint Complete remission of a metastatic pancreatic carcinoma after modified G-FLIP therapy
    Ingo Alldinger
    Department of General and Visceral Surgery, University Hospital Dusseldorf, Dusseldorf, Germany
    Chemotherapy 53:356-9. 2007
    ..The patient underwent surgery and the complete remission could be proven histologically. The administered chemotherapy was very effective and is even more attractive since it could be administered without admission to hospital...
  53. ncbi request reprint [Refractory anemia (RA) and refractory cytopenia with multilineage dysplasia (RCMD) in WHO classification: comparison between Japanese and German cases]
    Akira Matsuda
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University
    Rinsho Ketsueki 45:268-73. 2004
  54. doi request reprint Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly
    Andrea Kuendgen
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstr 5, Dusseldorf 40225, Germany
    Cancer Treat Rev 35:97-120. 2009
    ..This review will identify subgroups not likely to benefit from intensive chemotherapy and highlight the efficacy and tolerability of new agents in the treatment of AML...
  55. doi request reprint Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
    Aristoteles Giagounidis
    Marienhospital Düsseldorf, Dusseldorf, Germany
    Ann Hematol 93:1-11. 2014
    ..In addition, we discuss how improved understanding of the mechanism of disease will facilitate clinicians' ability to predict/monitor response and identify patients at risk of relapse. ..
  56. pmc Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange
    Norbert Gattermann
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Eur J Haematol 88:260-8. 2012
    ..These studies demonstrate that deferasirox used in physicians' medical practices is effective in managing iron burden in transfusion-dependent patients with MDS...
  57. ncbi request reprint Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer
    Ulrich Peter Rohr
    Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich Heine Universitat Dusseldorf, Duesseldorf, Germany
    Int J Cancer 111:259-63. 2004
    ..004) for overall survival next to TNM classification (p = 0.001) and performance status (p < 0.001)...
  58. ncbi request reprint [Myelodysplastic syndromes. Diagnosis and therapeutic strategies]
    Carlo Aul
    Medizinische Klinik II, St Johannes Hospital Duisburg, Germany
    Med Klin (Munich) 97:666-76. 2002
    ..The purpose of this review is to summarize the diagnostic work-up as well as current approaches to the treatment of MDS...
  59. ncbi request reprint Secondary acute myeloid leukaemia with monosomy 7 in identical adult twins
    Gernot Seipelt
    Universitätsklinik Frankfurt, Medizinische Klinik III, Hämatologie Onkologie, Frankfurt M, Germany
    Br J Haematol 116:338-40. 2002
    ..Three months later an allogeneic stem cell transplantation from a niece was performed, resulting in CR of the secondary AML...
  60. ncbi request reprint Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study
    Aristoteles A N Giagounidis
    St Johannes Hospital, Medizinische Klinik II, An der Abtei 7 11, 47166, Duisburg, Germany
    Ann Hematol 84:389-94. 2005
    ..Based on these results, the combination of ATRA and tocopherol-alpha is not recommended for the treatment of del(5q) MDS...
  61. ncbi request reprint Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7
    Sabine Knipp
    Haematologica 90:691-3. 2005
    ..Long-term treatment with azathioprine seems to be associated with an increased risk of MDS and subsequent leukemic transformation...
  62. ncbi request reprint Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
    Akira Matsuda
    Division of Hematology, Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, 350 0495, Japan
    Blood 106:2633-40. 2005
    ..In conclusion, our results indicate that the clinical features of Japanese patients with FAB-RA differ from those of German patients...
  63. ncbi request reprint A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
    Pierre Fenaux
    Hopital Avicenne, Paris, France
    Blood 109:4158-63. 2007
    ..In this study, durable responses and acceptable side effects were observed. Tipifarnib is an active agent for the treatment of patients with intermediate- to high-risk MDS...
  64. ncbi request reprint Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome
    Sabine Knipp
    Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011 Lausanne, Switzerland
    Leuk Res 32:33-7. 2008
    ..00005). Median survival of patients with PB was not different from that of RAEB I. We therefore propose to consider patients with PB, regardless of medullary blast, as RAEB I...
  65. ncbi request reprint Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies
    Aristoteles A N Giagounidis
    St Johannes Hospital, Medizinische Klinik II, Duisburg, Germany
    Clin Cancer Res 12:5-10. 2006
    ..The data provide important new insights into the pathobiology of 5q chromosomal deletions in myeloid malignancies...
  66. ncbi request reprint Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
    Luca Malcovati
    Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy
    J Clin Oncol 25:3503-10. 2007
    ....
  67. ncbi request reprint Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH
    Christina Evers
    Institute of Human Genetics and Anthropology, Heinrich Heine University Duesseldorf, 40225 Duesseldorf, Germany
    Genes Chromosomes Cancer 46:1119-28. 2007
    ..In addition, the high sensitivity of this method enables the study of whole bone marrow cells from MDS patients, a disease with a low blast count...
  68. ncbi request reprint New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
    Detlef Haase
    Department of Hematology and Oncology, University of Gottingen, Gottingen, Germany
    Blood 110:4385-95. 2007
    ..Our analyses offer new insights into the prognostic significance of rare chromosomal abnormalities and specific karyotypic combinations in MDS...
  69. ncbi request reprint High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable
    Norbert Gattermann
    Blood 109:1334-5. 2007
  70. ncbi request reprint Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Leuk Res 31:727-36. 2007
    ..Respective algorithms and recommendations should facilitate diagnostic and prognostic evaluations in MDS, selection of patients for therapies, and the conduct of clinical trials...
  71. ncbi request reprint Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Mignon L Loh
    Department of Pediatrics, University of California, San Francisco, CA, USA
    Leuk Res 29:459-62. 2005
    ..Here, we investigated contribution of PTPN11 mutations to adult MDS and CMML pathogenesis. Our results indicate that PTPN11 lesions might play a role in adult MDS/CMML pathogenesis but do not represent a major molecular event...
  72. doi request reprint Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
    Ghulam J Mufti
    Department of Haematology, King s College Hospital, Denmark Hill, London, SE5 9RS United Kingdom
    Haematologica 93:1712-7. 2008
    ..Recommendations should be applied in the context of the WHO classification...
  73. ncbi request reprint Levels of circulating endothelial adhesion molecules in patients with myelodysplastic syndromes
    Thomas Südhoff
    Department of Internal Medicine, Knappschaftskrankenhaus Bochum Langendreer, Ruhr University Bochum, D 44892 Bochum, Germany
    Int J Oncol 20:167-72. 2002
    ..Thus, increased leukocyte endothelial interaction may account for the higher incidence of extramedullary infiltrations in this MDS subtype...
  74. ncbi request reprint Mutation analysis of CUTL1 in childhood myeloid neoplasias with monosomy 7
    Simone Hindersin
    Leuk Res 31:1323-4. 2007
  75. ncbi request reprint Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
    Sabine Knipp
    Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011, Lausanne, Switzerland
    Leuk Res 31:1585-7. 2007
    ..002 mg/l (0.027 micromol/l), both representing about 14% of blood levels. ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia...
  76. ncbi request reprint New prognostic parameters for chronic myelomonocytic leukemia
    Ulrich Germing
    Blood 100:731-2; author reply 732-3. 2002
  77. ncbi request reprint Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis
    Norman Putzki
    Department of Neurology, University Hospital Essen, Essen, Germany
    Mult Scler 12:363-6. 2006
    ..Cases suggest a time- and dose-dependent risk of sMDS in long-term therapy of MS with Aza. Long-term Aza therapy needs careful monitoring...
  78. ncbi request reprint Perspectives in the prognostication of myelodysplastic syndromes
    Ulrich Germing
    Haematologica 90:1157-9. 2005
  79. ncbi request reprint Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
    Azim Mohamedali
    Department of Haematological Medicine, King s College Hospital, King s College London School of Medicine, Denmark Hill, London, United Kingdom
    Blood 110:3365-73. 2007
    ..001). We show, for the first time, that SNP microarray analysis in low-risk MDS patients reveals hitherto unrecognized UPD and CN changes that may allow stratification of these patients for early therapeutic interventions...
  80. ncbi request reprint Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients
    Christian Steidl
    Department of Hematology and Oncology, Georg August University, Goettingen, D 37099 Göttingen, Germany
    Leuk Res 29:987-93. 2005
    ..In summary, our data suggest the examination of at least 20 metaphases in MDS...
  81. pmc Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease
    Manuel Aivado
    Proteomics Core and Department of Medical Oncology, Dana Farber Harvard Cancer Center, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 104:1307-12. 2007
    ..Subtype analyses revealed that these two proteins have decreased serum levels in advanced MDS, suggesting the possibility of a concerted disturbance of transcription or translation of these chemokines in advanced MDS...
  82. ncbi request reprint Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes
    Ulrich Germing
    Br J Haematol 138:399-400. 2007
  83. doi request reprint JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
    Annette H Schmitt-Graeff
    Institute of Pathology, University Hospital, D 79108 Freiburg, Germany
    Haematologica 93:34-40. 2008
    ..To determine the frequency and the prognostic significance of this mutation, we retrospectively evaluated 23 patients with platelet counts more than 600 x 10(9)/L, 15% ringed sideroblasts or more, and at least erythroid marrow dysplasia...